BLOG: With our new grants for research into the uses of liquid biopsies, Dr Sophie Lutter explains why they allow scientists to read clues about how a prostate cancer responds to treatment, and how they could revolutionise the way men are diagnosed and monitored with the disease.
BLOG: Following a report in the Mirror yesterday of a massive rise in diagnosis of advanced prostate cancer in the United States and a call for more PSA screening there, our resident expert Dr Sophie Lutter cautions against such an approach here.
BLOG: From training up radiologists to working alongside commissioners and the NHS, Dr Sophie Lutter explains how we're making sure the results of the PROMIS trial are rolled out into real-life hospitals as soon as they've been peer-reviewed, and why rushing it could do more harm than good.
BLOG: The revolutionary ADRRAD trial turns conventional thinking about advanced prostate cancer on its head, attempting to overcome a disease that's considered terminal. Dr Sophie Lutter looks behind the scenes at what makes this such a game-changing enterprise and why it represents the perfect dance between medicine and science.
BLOG: In the fourth part of her series on our new strategy, Sophie Lutter explains why support for today is as much a priority as planning for tomorrow.
BLOG: Sophie Lutter explains what we're doing to improve the availability of PSA testing to men who want or need it and why, on its own, it's still not the answer to creating a national screening programme for prostate cancer.
BLOG: In the third part of her blog about our ambitious plan to tame prostate cancer in ten years, Sophie Lutter outlines the reasons behind our prevention strategy.
BLOG: In the second part of her blog about our new strategy, Sophie Lutter discusses what we'll be doing on clinical trials and advanced prostate cancer.
BLOG: In the first part of our examination of how we shift the science to tame prostate cancer in ten years, Sophie Lutter discusses the role of better diagnosis and the PSA test.
BLOG: Is radiotherapy a safe option for men with prostate cancer? Sophie Lutter delves behind the headlines to see what the science say